This comprises an important field of research in the light of increasing resistance against antibiotics. Recently the startup presented its seed financing investors. In addition to the Austrian Research Promotion Agency FFG, Austria Wirtschaftsservice (aws) and private investors are also on board. Together they made about EUR 4 million available to the firms for further developing new therapeutics. At present Phagomed is evaluating three potential product candidates.